Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
- PMID: 24415568
- PMCID: PMC3937859
- DOI: 10.1212/WNL.0000000000000101
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Abstract
Objective: To evaluate clinical features among patients with neuromyelitis optica spectrum disorders (NMOSD) who have myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) antibodies, or seronegativity for both antibodies.
Methods: Sera from patients diagnosed with NMOSD in 1 of 3 centers (2 sites in Brazil and 1 site in Japan) were tested for MOG and AQP4 antibodies using cell-based assays with live transfected cells.
Results: Among the 215 patients with NMOSD, 7.4% (16/215) were positive for MOG antibodies and 64.7% (139/215) were positive for AQP4 antibodies. No patients were positive for both antibodies. Patients with MOG antibodies represented 21.1% (16/76) of the patients negative for AQP4 antibodies. Compared with patients with AQP4 antibodies or patients who were seronegative, patients with MOG antibodies were more frequently male, had a more restricted phenotype (optic nerve more than spinal cord), more frequently had bilateral simultaneous optic neuritis, more often had a single attack, had spinal cord lesions distributed in the lower portion of the spinal cord, and usually demonstrated better functional recovery after an attack.
Conclusions: Patients with NMOSD with MOG antibodies have distinct clinical features, fewer attacks, and better recovery than patients with AQP4 antibodies or patients seronegative for both antibodies.
Figures


Comment in
-
The two faces of neuromyelitis optica.Neurology. 2014 Feb 11;82(6):466-7. doi: 10.1212/WNL.0000000000000114. Epub 2014 Jan 10. Neurology. 2014. PMID: 24415570 No abstract available.
-
MOG-IgG in neuromyelitis optica.J Neurol. 2014 Mar;261(3):640-2. doi: 10.1007/s00415-014-7277-z. J Neurol. 2014. PMID: 24532204 No abstract available.
-
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.Neurology. 2014 Jul 29;83(5):475. doi: 10.1212/WNL.0000000000000636. Neurology. 2014. PMID: 25074893 No abstract available.
-
Author response.Neurology. 2014 Jul 29;83(5):475-6. Neurology. 2014. PMID: 25215376 No abstract available.
-
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.Neurology. 2014 Sep 16;83(12):1122. doi: 10.1212/WNL.0000000000000830. Neurology. 2014. PMID: 25224530 No abstract available.
-
Author response.Neurology. 2014 Sep 16;83(12):1122-3. Neurology. 2014. PMID: 25356464 No abstract available.
References
-
- Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107–1114 - PubMed
-
- Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805–815 - PubMed
-
- Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235–1243 - PubMed
-
- Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273–1277 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical